KDM1A and leukemia: TCP has more recently been shown to inhibit LSD1, decreasing H3K4 methylation94, and Schenket al. have demonstrated that, when added to ATRA, TCP greatly potentiates the differentiation response in non-APL AML cell lines and primary patient samples, leading to decreased leukemia burden and elimination of leukemia-initiating cells93.